Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hyperpolarized Carbon-13 Alpha-ketoglutarate Metabolic Imaging in IDH Mutant Glioma

NCT05851378 is registered in ClinicalTrials.gov with Robert Bok, MD, PhD as lead sponsor.

NCT NCT05851378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05851378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hyperpolarized Carbon-13 Alpha-ketoglutarate Metabolic Imaging in IDH Mutant Glioma
Lead sponsor
Robert Bok, MD, PhD
Phase
Phase 1
Overall status
Completed
Start date
April 11, 2023
Completion date
January 31, 2026
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult gliomas, mixed